Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major economic releases or central-bank comments were published in the past hour.
  • Equity indices showed limited movement and low volatility.
  • Global bond yields were mostly unchanged with no fresh drivers for rate moves.
  • Oil and metals traded flat with no fresh supply or demand developments.
  • FX markets were subdued with the dollar unchanged against major peers.
  • Political and geopolitical calendars recorded no new events or escalations in the past hour.

Latest Articles

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Oct 7, 2026
Maya Rios
Press Releases

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Artelo Biosciences announced it will deliver its first-ever company presentation at BIO-Europe 2026, showcasing clinical and nonclinical data on its novel FABP5 inhibitor ART26.12. The company highlighted the drug's favorable safety profile, dosing flexibility, and potential efficacy in treating chemotherapy-induced peripheral neuropathy and osteoa…

ARTL
Tessera: Zorronet Reports Growing Operational Deployments of Its Natural-Language AI Platform in Defense and Critical Infrastructure
Oct 7, 2026
Caleb Monroe
Press Releases

Tessera: Zorronet Reports Growing Operational Deployments of Its Natural-Language AI Platform in Defense and Critical Infrastructure

Tessera Defense and Homeland Security's subsidiary, Zorronet Ltd., reports significant operational deployments of its advanced AI intelligence platform integrating natural-language processing, video analytics, and no-code tools. The platform is being adopted by customers in critical infrastructure, defense, public safety, transportation, and energy…

HLSQ
WISeSat.Space to Ring the Nasdaq Opening Bell on October 9 and Highlight Secure Space Infrastructure Strategy at Convene Quantum Space Security Roundtable
Oct 7, 2026
Maya Rios
Press Releases

WISeSat.Space to Ring the Nasdaq Opening Bell on October 9 and Highlight Secure Space Infrastructure Strategy at Convene Quantum Space Security Roundtable

WISeSat.Space Holdings Corp. (NASDAQ: SAIQ) will ring the Nasdaq Opening Bell on October 9, 2026, to mark its listing and outline its strategy for developing quantum-resilient space communication infrastructure. The company will also host a Quantum Space Security Roundtable featuring experts in space, quantum tech, and cybersecurity to discuss prot…

SAIQ
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Oct 7, 2026
Priya Menon
Press Releases

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

Clearmind Medicine Inc. announced that it has submitted recommendations to the U.S. FDA advocating for new regulatory pathways and broader patient access to non-hallucinogenic psychedelic-derived neuroplastogens for treating Alcohol Use Disorder and other neuropsychiatric conditions. The company highlighted promising clinical trial results from Yal…

CMND
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio
Oct 7, 2026
Priya Menon
Press Releases

Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio

Wellspect HealthCare, a subsidiary of Dentsply Sirona, announced that its Surity™ portfolio of urinary management products is now eligible for traditional Medicare reimbursement for medically necessary cases. This milestone expands access to non-invasive urinary incontinence solutions for over 13 million affected patients in the U.S., reducing barr…

XRAY
OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region
Oct 7, 2026
Leila Farooq
Press Releases

OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region

OneMedNet Corporation announced a strategic partnership with Mediplexus, a Korean healthcare data company, to distribute its U.S.-sourced Real World Data in Korea and the broader Asia Pacific region. This agreement marks OneMedNet's 11th channel partner and aims to broaden collaborative data applications for Korean biopharma, medtech, and medical A…

ONMD
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Oct 7, 2026
Nina Shah
Press Releases

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Ultragenyx Pharmaceutical announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The PRV was granted following FDA approval of Genelycos™, a treatment for glycogen storage disease type Ia. The sale is expected to provide non-dilutive capital to advance Ultragenyx's pipeline and support pr…

RARE
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Oct 7, 2026
Marcus Reed
Press Releases

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Propanc Biopharma announced promising preclinical data for its lead candidate PRP, demonstrating over 90% tumor growth inhibition, reduced metastases, and tumor microenvironment remodeling in pancreatic ductal adenocarcinoma models. PRP offers a distinct mechanism from Revolution Medicines' FDA-approved daraxonrasib, targeting cancer pathways not a…

PPCB
TOMI Environmental Solutions Confirms Readiness to Support Biosecurity Preparedness and Front-Line Response Worldwide
Oct 7, 2026
Derek Hwang
Press Releases

TOMI Environmental Solutions Confirms Readiness to Support Biosecurity Preparedness and Front-Line Response Worldwide

TOMI Environmental Solutions, trading on NASDAQ under TOMZ, confirmed its preparedness to support global biosecurity efforts through its disinfection technology and services. The company highlighted its capability to assist hospitals, laboratories, and government agencies in response to potential outbreaks, using its SteraMist systems. This announc…

TOMZ
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Oct 7, 2026
Hana Yamamoto
Press Releases

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx has enrolled the first patient in the PRISM-TAMP investigator-initiated trial, evaluating neoadjuvant intra-arterial gemcitabine delivery via their TAMP platform for borderline resectable pancreatic ductal adenocarcinoma. This marks a clinical expansion beyond their ongoing Phase III for locally advanced pancreatic cancer, with results ant…

RNXT